Drug Trial Radar · NCT03785587
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Last checked: Nov 20, 2026Latest source record: Mar 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Dec 21, 2018
Primary completion
Sep 6, 2019
Study completion Sep 6, 2019
Sponsor
- Lead sponsor
- Botanix PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Dec 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of the sweat glands. Sofpironium bromide (BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis. This Phase 2 study will assess the long-term safety, tolerability, pharmacokinetics and efficacy of sofpironium bromide gel applied topically to pediatric subjects with axillary hyperhidrosis.
Conditions
- Primary Axillary Hyperhidrosis
Interventions
Sofpironium Bromide Gel, 15%Drug
Sofpironium Bromide Gel, 15%
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Participants With Treatment Emergent Adverse Events (All TEAEs).Time frame: Through study completion (24 weeks).
- The Number of Participants With Dermal Tolerability Symptoms of Burning, Stinging, Itching, Scaling or Erythema to the Axillae.Time frame: Through study completion (24 weeks).
- The Systemic Exposure (Ctrough) of Sofpironium and Its Primary Metabolite (BBI-4010)Time frame: Through study completion (24 weeks).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Northwest Arkansas Clinical Trials Center
Rogers, Arkansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.